S
688289
vs
S
Shanghai Composite
Over the past 12 months, Sansure Biotech Inc has underperformed Shanghai Composite, delivering a return of -16% compared to the Shanghai Composite's +22% growth.
Stocks Performance
688289 vs Shanghai Composite
Performance Gap
688289 vs Shanghai Composite
Performance By Year
688289 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sansure Biotech Inc
Glance View
Nestled in the bustling hub of China's life sciences innovation, Sansure Biotech Inc. has emerged as a pivotal player in the biotechnology landscape. Founded with a vision to harness cutting-edge technology for health diagnostics, the company has developed a comprehensive suite of diagnostic products and solutions. At its core, Sansure specializes in the research, development, and commercialization of in-vitro diagnostic reagents and instruments. By leveraging its proprietary technologies, the company addresses pressing global health challenges with precision diagnostics that span infectious diseases, oncology, and genetic testing, among others. Its portfolio encompasses both equipment and consumables, offering end-to-end solutions that enable healthcare providers to deliver accurate and timely diagnoses. Sansure's business model is intricately woven into the fabric of both innovation and distribution. The company thrives by consistently innovating its product line to keep pace with global health demands while optimizing its production processes for scale and efficiency. Revenue streams flow from the sale of its diagnostic kits and instruments, which are widely adopted in hospitals, clinics, and laboratories. Collaborations with research institutions and healthcare bodies have further cemented its status as a trusted partner in public health. Through strategic partnerships and an expanding international footprint, Sansure has built a robust distribution network that ensures its technologies are accessible to a diverse market, thus driving its financial growth and solidifying its standing in the biotech industry.
